诺沃诺迪斯克和Emcure在印度推出了减肥注射类西马格卢提德, 增加了Emcure的库存. Novo Nordisk and Emcure launch semaglutide weight-loss injection in India, boosting Emcure’s stock.

诺沃诺迪斯克与印度的Emcure药品公司合作,在印度推出Poviztra,这是一种2. 4毫克的减肥类半质注射剂,与其现有的Wegovy治疗分开销售. Novo Nordisk has partnered with India’s Emcure Pharmaceuticals to launch Poviztra, a 2.4-milligram semaglutide injection for weight loss, in India, marketed separately from its existing Wegovy treatment. 虽然每月的价格为26,015卢比, 但药价未公布. The drug’s price was not disclosed, though Wegovy costs 26,015 rupees monthly. 该公告将Emcure的股票增加了6.5%。 The announcement boosted Emcure’s stock by 6.5%. 这是继Eli Lilly与Cipla就其减重药物进行类似合作之后发生的,这表明印度减重药品市场日益扩大的竞争。 This follows Eli Lilly’s similar collaboration with Cipla for its weight-loss drug, signaling growing competition in India’s expanding weight-loss medication market.